Slide 1: Announcement of Q2 2008 Results
Announcement of Q2 2008 Results Conference Call July 15, 2008 | 3:00 p.m. CEST Dr. Axel Herberg, CEO Hans-Jürgen Wiecha, CFO 0
Slide 2: Agenda
Agenda Business Highlights Q2 2008 Dr. Axel Herberg, CEO Financial Overview Q2 2008 Hans-Jürgen Wiecha, CFO Confirmation of Guidance FY 2008 Dr. Axel Herberg, CEO 1
Slide 3: Gerresheimer demonstrates operational strength in Q2
Gerresheimer demonstrates operational strength in Q2 Net sales grew by 12.8% to 276.3m (at constant FX rate: +16.5%) All segments contributed to sales and earnings growth Strong operating performance: Adjusted EBITDA growth of 20.2% to 53.6m Adjusted EBITDA margin expanded from 18.2% in Q2 2007 to 1
Slide 4: Strong performance of Gerresheimer divisions in Q2
Strong performance of Gerresheimer divisions in Q2 Tubular Glass: RTF-syringes production lines working at full capacity 3rd RTF line on track for ramp up of production in Q1 2009 Continued high sales growth of vials Plastic Systems: Strong growth in Medical Plastic Systems Successful integration of
Slide 5: Successful divestment of non-core activities
Successful divestment of non-core activities Consumer Healthcare business Reasons for disposal: Lack of strategic fit Missing synergies to core business Margin below group requirements Financial impact: 24m in FY 2007 sales // Group sales 2008 down 12m Book loss of 4.6m Aluminum Packaging business S
Slide 6: Agenda
Agenda Business Highlights Q2 2008 Dr. Axel Herberg, CEO Financial Overview Q2 2008 Hans-Jürgen Wiecha, CFO Confirmation of Guidance FY 2008 Dr. Axel Herberg, CEO 5
Slide 7: Group: Further growth in sales and profitability
Group: Further growth in sales and profitability Net sales and adjusted EBITDA ;m Net sales growth at Adj. EBITDA margin: constant exchange Q2 2008: 19.4% rate: 16.5% Q2 2007: 18.2% Strong growth in net sales driven by +12.8% high demand for our 276.3 pharma and cosmetic 245.0 products successful in
Slide 8: Tubular Glass: Sales pushed by demand for RTF-syringes
Tubular Glass: Sales pushed by demand for RTF-syringes Net sales and adjusted EBITDA ;m Net sales growth at Adj. EBITDA margin: constant exchange Q2 2008: 24.9% rate: 15.6% Q2 2007: 22.3% Sales increase fueled by +10.3% strong revenue growth in 70.7 78.0 RTF-syringes (+36.5%) strong sales growth of
Slide 9: Plastic Systems: Medical Plastic Systems drive sales in Q2
Plastic Systems: Medical Plastic Systems drive sales in Q2 Net sales and adjusted EBITDA ;m Net sales growth at Adj. EBITDA margin: constant exchange Q2 2008: 19.1% rate: 17.4% Q2 2007: 18.5% Strong growth in inhalation, +17.6% diabetes care and molecular 93.6 diagnostics 79.6 EDP and Allplas integr
Slide 10: Moulded Glass: Ongoing strong growth
Moulded Glass: Ongoing strong growth Net sales and adjusted EBITDA ;m Net sales growth at Adj. EBITDA margin: constant exchange Q2 2008: 21.7% rate: 9.7% Q2 2007: 20.7% Strong sales growth coupled with +6.1% significant increase in adjusted EBITDA margin 85.6 80.7 Growth attributable to strong deman
Slide 11: Life Science Research: Continued momentum in Q2 2008
Life Science Research: Continued momentum in Q2 2008 Net sales and adjusted EBITDA ;m Net sales growth at Adj. EBITDA margin: constant exchange Q2 2008: 11.9% rate: +77.2% Q2 2007: 10.1% Net sales soared by 51.7% through +51.7% 22.6 merger with Life Science business of Thermo Fisher 14.9 prospering
Slide 12: Operating performance boosts earnings in Q2 2008
Operating performance boosts earnings in Q2 2008 ;m Q2 2008 Q2 2007 FY 2007 Net sales 276.3 245.0 +12.8% 957.7 Adjusted EBITDA1 53.6 44.6 +20.2% 181.6 Margin 19.4% 18.2% 19.0% Adjusted EBITA2 34.9 28.8 +21.2% 116.6 Margin 12.6% 11.8% 12.2% Profit from operations 18.6 12.4 +50.0% 53.3 Net income 5.6
Slide 13: Financial metrics allow for further growth
Financial metrics allow for further growth Q2 as of Q2 as of FY 2007 as of ;m May 31, 2008 May 31, 2007 Nov 30, 2007 Equity 500.2 31.8 >100% 499.9 Equity ratio in % 34.0 2.3 34.8 Net working capital1 216.5 168.2 +28.7% 179.8 in % of LTM net sales 21.1 21.7 18.8 Net financial debt2 456.2 838.5 -45.6%
Slide 14: Q1-Q2 2008: Substantially increased profits
Q1-Q2 2008: Substantially increased profits ;m Q1-Q2 2008 Q1-Q2 2007 FY 2007 Net sales 515.4 447.3 +15.2% 957.7 Adjusted EBITDA1 96.6 80.3 +20.3% 181.6 Margin 18.7% 18.0% 19.0% Adjusted EBITA2 60.4 50.7 +19.1% 116.6 Margin 11.7% 11.3% 12.2% Profit from operations 33.5 23.8 +40.8% 53.3 Net income 8.1
Slide 15: Agenda
Agenda Business Highlights Q2 2008 Dr. Axel Herberg, CEO Financial Overview Q2 2008 Hans-Jürgen Wiecha, CFO Confirmation of Guidance FY 2008 Dr. Axel Herberg, CEO 14
Slide 16: Confirmation of Guidance FY 2008
Confirmation of Guidance FY 2008 Growth rate of continuing business: 14-16% at constant FX rate Growth rate reflecting recent divestments: Net Sales 12.5-14.5% at constant FX rate Growth rate reflecting recent divestments and FX rate of ;1 = $1.55: 9-11% Mid 19% Adj. EBITDA margin Expected investmen
Slide 17: Financial Calendar 2008 / 2009
Financial Calendar 2008 / 2009 October 15, 2008 Interim Report 3rd Quarter 2008 October 23+24, 2008 Capital Markets Day 2008 February 17, 2009 Full Year Results 2008 April 29, 2009 Annual General Meeting 16
Slide 18: Investor Relations Contact Details
Investor Relations Contact Details Phone: +49 211 6181 – 257 Fax: +49 211 6181 – 121 E-mail: investorrelations@gerresheimer.com Please visit our IR website: www.gerresheimer.com/ir 17
Slide 19: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or
Slide 20: BACKUP Q1-Q2 2008: Gerresheimer Group
BACKUP Q1-Q2 2008: Gerresheimer Group Net sales and adjusted EBITDA ;m Adj. EBITDA margin: Net sales growth at constant Q1-Q2 2008: 18.7% exchange rate: 18.9% Q1-Q2 2007: 18.0% +15.2% 515.4 447.3 +20.3% 80.3 96.6 Net sales Adj. EBITDA1 Q1-Q2 2007 Q1-Q2 2008 1 Earnings before financial result, income
Slide 21: Q1-Q2 2008 Tubular Glass, Plastic Systems
Q1-Q2 2008 Tubular Glass Plastic Systems Net sales and adjusted EBITDA Net sales and adjusted EBITDA ;m ;m Net sales growth at Adj. EBITDA margin: Net sales growth at Adj. EBITDA margin: constant exchange Q1-Q2 2008: 24.4% constant exchange Q1-Q2 2008: 18.7% rate: 15.2% Q1-Q2 2007: 23.5% rate: 25.3%
Slide 22: Q1-Q2 2008 Moulded Glass, Life Science Research
Q1-Q2 2008 Moulded Glass Life Science Research Net sales and adjusted EBITDA Net sales and adjusted EBITDA ;m ;m Net sales growth at Adj. EBITDA margin: Net sales growth at Adj. EBITDA margin: constant exchange Q1-Q2 2008: 21.2% constant exchange Q1-Q2 2008: 11.5% rate: 8.8% Q1-Q2 2007: 19.4% rate:
Slide 23: Q1-Q2 2008: Favorable key metrics underline success
Q1-Q2 2008: Favorable key metrics underline success Q1-Q2 as of Q1-Q2 as of FY 2007 as of ;m May 31, 2008 May 31, 2007 Nov 30, 2007 Equity 500.2 31.8 >100% 499.9 Equity ratio in % 34.0 2.3 34.8 Net working capital1 216.5 168.2 +28.7% 179.8 in % of LTM net sales 21.1 21.7 18.8 Net financial debt2 456